新加坡媒体：中国生物技术惊人进步正改变全球药物研发

Core Insights - The global biotechnology industry is undergoing a structural transformation, with Chinese pharmaceutical companies increasingly challenging Western dominance in innovation [1] - In 2024, the number of innovative drugs entering the R&D phase in China has surpassed 1,250, exceeding the EU and nearing the US's 1,440 [1] - The rapid development and attractiveness of these new drugs span various treatment areas, including cancer and weight loss, gaining recognition from Western regulatory bodies and multinational pharmaceutical companies [1] Group 1 - The number of new drugs in China's global drug development pipeline was only 160 in 2015, accounting for less than 6% [1] - Reforms in China's drug regulatory system have accelerated review processes, improved data quality, and enhanced regulatory transparency [1] - Government initiatives aimed at boosting manufacturing levels in key areas have stimulated investment in the biotechnology sector, leading to a wave of innovation driven by returning overseas scientists and entrepreneurs [1] Group 2 - China has become the leading location for clinical research globally, initiating the most new trials since 2021 [2] - Among the 50 companies generating the most innovative drug candidates from 2020 to 2024, 20 are based in China [2] - The perception of high-quality innovation in China's biotechnology sector is expected to become a recognized norm as the industry continues to develop [2]